Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8475517 | 0.85 | PTGS2 (0.38) | TAAR1PTGS2PDE3BPDE3A | |
| SCHEMBL2281116 | 0.80 | — | — | |
| SCHEMBL2283977 | 0.78 | PDE3B (0.35) | PTGS2PDE3BPDE3A | |
| SCHEMBL2288244 | 0.78 | TAAR1 (0.37) | TAAR1PTGS2PDE3BPDE3A | |
| SCHEMBL2287590 | 0.76 | KDM4E (0.34) | TAAR1PTGS2PDE3BPDE3A | |
| SCHEMBL2281068 | 0.76 | PTGS2 (0.32) | TAAR1PTGS2PDE3BPDE3AL3MBTL1 | |
| SCHEMBL4156609 | 0.76 | HTR2A (0.36) | — | |
| SCHEMBL2285493 | 0.75 | MAPT (0.32) | L3MBTL1 | |
| SCHEMBL2288733 | 0.74 | TUBB1 (0.33) | TDP1L3MBTL1 | |
| SCHEMBL27863792 | 0.73 | HTR2A (0.42) | PTGS2TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989394-B2 | Substituted 1-(azolin-2-yl)-amino-2-aryl-1-hetaryl-ethane compounds | BASF SE (DE) | 2011-08-02 | — | — | US | disclosed |
| US-20090131256-A1 | Substituted 1-(azolin-2-yl)-amino-2-aryl-1-hetaryl-ethane Compounds | BASF SE (DE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131256-A1 | Substituted 1-(azolin-2-yl)-amino-2-aryl-1-hetaryl-ethane Compounds | AAAS, AIPL1, ATXN2 | TAAR1 252/4885PTGS2 125/4885PDE3B 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.